Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study | Alzheimer's Research & Therapy
Traitement anti-Alzheimer Lecanemab : 3 questions au Pr Bruno Vellas, co-auteur de l'étude – SFGG
Lecanemab: Appropriate Use Recommendations | The Journal of Prevention of Alzheimer's Disease
Alzheimer's Drug Slows Cognitive Decline in Key Study - The New York Times
Alzheimer's drug lecanemab slows cognitive decline but concerns linger | New Scientist
A hope for Alzheimer's: Lecanemab breakthrough from the research community - Federation of European Neuroscience Societies
Full Phase 3 Trial Data Support Lecanemab for Early Alzheimer's | FDA Ruling on Dementia Treatment Approval Expected in January | Alzheimer's News Today
Alzheimer's disease: FDA approves Biogen, Eisai treatment lecanemab
Heralded Alzheimer's Drug Works, but Safety Concerns Loom | Scientific American
Lecanemab can; now the wait for details begins | Evaluate
Accelerated FDA Approval Sought for Lecanemab, Alzheimer's Treatment
FDA approves lecanemab for the treatment of Alzheimer's disease | VJDementia
Eisai reports positive results from their CLARITY AD Phase 3, lecanemab study | Alzheimer's Disease International (ADI)
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease At Clinical Trials On Alzheimer's Disease (Ctad) Conference | Biogen
Lecanemab trial 'pivotal' for other therapy developers targeting Alzheimer's disease
Press release New data on lecanemab to be presented at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference
Press release Latest lecanemab data to be presented at the AD/PD™ congress
Advances in Clinical and Experimental Medicine
Lecanemab: Alzheimer drug approved in U.S.; what it means for Canada | CTV News
Press release New lecanemab-data presented at the AD/PD™ 2023 conference
Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review - Selia Chowdhury, Nurjahan Shipa Chowdhury, 2023
Paul Thompson on X: "BREAKING NEWS: New #Alzheimer drug #Lecanemab slows cognitive decline (18-month change in CDR-SB) by 27%, drastically lowers brain amyloid load by 59 centiloids to 23 (below PET amyloid
Eisai US on LinkedIn: EISAI TO PRESENT NEW DATA FROM LEQEMBI® (LECANEMAB-IRMB) PHASE 3 CLARITY…
